Ruxolitinib + Hydroxycarbamide + Interferon-Alpha

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Polycythemia Vera

Conditions

Polycythemia Vera

Trial Timeline

Oct 25, 2019 → Apr 1, 2030

NCT ID

NCT04116502

About Ruxolitinib + Hydroxycarbamide + Interferon-Alpha

Ruxolitinib + Hydroxycarbamide + Interferon-Alpha is a phase 3 stage product being developed by Novartis for Polycythemia Vera. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04116502. Target conditions include Polycythemia Vera.

What happened to similar drugs?

2 of 16 similar drugs in Polycythemia Vera were approved

Approved (2) Terminated (1) Active (14)

🔄Sapablursen + PlaceboOno PharmaceuticalPhase 3

🔄ruxolitinib tabletsNovartisPhase 3

🔄RuxolitinibNovartisPhase 3

✅HydroxyureaNovartisApproved

🔄Best Available Therapy + RuxolitinibNovartisPhase 3

🔄PEGASYS + Hydroxyurea + AspirinRochePhase 3

🔄Pegylated-Proline-Interferon alpha-2b in a Pre-filled PenPharmaEssentiaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04116502	Phase 3	Recruiting	Oct 25, 2019	Apr 1, 2030	Polycythemia Vera

Competing Products

20 competing products in Polycythemia Vera

See all competitors

Product	Company	Stage	Hype Score
Sapablursen + Placebo	Ono Pharmaceutical	Phase 3	47
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Bomedemstat	Merck	Phase 2	35
ruxolitinib tablets	Novartis	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Ruxolitinib	Novartis	Phase 3	40
Ruxolitinib + BAT	Novartis	Phase 2	39
Hydroxyurea	Novartis	Approved	35
Best Available Therapy + Ruxolitinib	Novartis	Phase 3	40
Smac Mimetic LCL161	Novartis	Phase 2	35
PEGASYS + Aspirin	Roche	Phase 2	35
RG7388 + Pegasys	Roche	Phase 1	29
Idasanutlin	Roche	Phase 2	27
PEGASYS + Hydroxyurea + Aspirin	Roche	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Phase 2	39
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen	PharmaEssentia	Phase 3	40
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)	PharmaEssentia	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Approved	50
P1101 + Low-dose aspirin	PharmaEssentia	Phase 2	35
P1101 (Ropeginterferon alfa-2b)	PharmaEssentia	Phase 3	47